Innoen 5% Glucose Injection

Adult administration

Administer 500 to 1000 mL intravenously per dose. The rate of intravenous drip should be less than 0.5 g/kg of glucose per hour. Use an appropriate amount for dissolving or diluting the injection. Adjust dosages as needed according to age and symptoms.

When opening the ampoule, glass fragments may enter; therefore, special care should be taken when using this medication in children and the elderly. Administering this medication intravenously, which contains glucose, may lead to a rapid drop in vitamin B1 (thiamine) levels, increasing the risk of serious deficiency symptoms. This medication should not be administered to patients with certain conditions such as storage dehydration, excessive fluid state, hyperglycemia, acidosis, hypokalemia, hyperosmolar coma, intolerance to glucose, anuria, or hepatic coma. Additionally, its hypertonic form should not be used in patients with spinal hemorrhage or intracranial hemorrhage. Patients who have a deficiency of potassium, phosphate, magnesium, or a tendency towards hyponatremia, as well as those with diabetes insipidus, renal failure, heart failure, severe malnutrition, sepsis, severe dehydration, or shock should use this medication with caution. Rapid or large volume infusions may cause electrolyte imbalances, and exceeding the recommended dose may elevate liver enzymes and lactic acid levels. This medication can cause various side effects such as dehydration, hyperosmolar state, polyuria, fluid overload, pulmonary edema, thrombosis, and pain at the injection site. Patients with intolerance to glucose should be cautious as blood sugar may rise sharply, leading to potential kidney damage. Long-term administration may affect insulin secretion; thus insulin should be administered if necessary. Blood sugar control status should be checked when used post-surgery or after trauma, or in patients with intolerance to glucose. Serum electrolytes, fluid balance, and blood sugar levels should be regularly monitored and the patient’s condition should be closely observed. During pregnancy, the risks to the fetus are not clearly known; therefore, it should only be used when the benefits of treatment outweigh the risks. When administered during childbirth, maternal and neonatal hyperglycemia and hypoglycemia may occur. Newborns, especially preterm or low-birth-weight infants, are at greater risk of hypoglycemia or hyperglycemia and should be carefully monitored for blood sugar levels. Elderly patients should use this medication with increased caution due to decreased bodily function. Overdose may lead to hyperglycemia or diabetic symptoms that may require insulin treatment. Subcutaneous injections should be avoided as they can induce severe circulatory problems and irritation; any remaining medication should be discarded after opened and should be used immediately. To minimize the risk of infection during injection, cleanliness should be maintained, and it is advisable to warm the medication to body temperature before use. When mixing with other medications, careful observation is required for potential chemical or physical reactions. Also, to reduce the risk of air embolism, care should be taken to prevent air remaining in the container from being injected.

Mild side effects

• Hypokalemia
• hypertonic coma
• acidosis
• dehydration
• hyperosmolar syndrome
• polyuria with glucose detection
• fluid or solute overload
• fluid electrolyte imbalance
• congestion
• pulmonary edema

This medication should be stored in a sealed container to prevent air or moisture from entering, kept away from direct sunlight, and stored at room temperature. Room temperature typically refers to a temperature range of 15 to 25 degrees Celsius, avoiding excessively hot or cold environments.

Appearance

A colorless and transparent injection solution filled in a plastic container made of high-density polyethylene that is semi-transparent on the outside.

Package unit

50, 100, 200, 500, 1000 milliliters